A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2004
12/29/2004	EP1490688A1 Novel compositions and methods in cancer associated with altered expression of prdm 11
12/29/2004	EP1490500A1 Novel compositions and methods in cancer associated with altered expression of tbx21
12/29/2004	EP1490490A2 Antisense iap nucleobase oligomers and uses thereof
12/29/2004	EP1490477A2 Redifferentiated cells for repairing cartilage defects
12/29/2004	EP1490474A2 Method for producing pseudo islets
12/29/2004	EP1490388A1 Novel compositions and methods in cancer associated with altered expression of kcnj9
12/29/2004	EP1490387A2 A human ribonucleotide reductase m2 subunit
12/29/2004	EP1490386A2 Novel polypeptides and nucleic acids encoding the same
12/29/2004	EP1490365A1 Azaindoles as inhibitors of c-jun n-terminal kinases
12/29/2004	EP1490338A1 Use of an alfa2-adrenoreceptor antagonist for cns-related diseases
12/29/2004	EP1490121A1 Drug delivery particle
12/29/2004	EP1490119A1 Tissue treatment
12/29/2004	EP1490107A1 Modulating angiogenesis
12/29/2004	EP1490097A1 Use of botulinum toxin for treating cardiovascular diseases
12/29/2004	EP1490093A1 Methods and compositions for the treatment of ischemia
12/29/2004	EP1490090A2 Active agent delivery systems and methods for protecting and administering active agents
12/29/2004	EP1490082A2 Compositions and methods for preventing and treating cancer via modulating ube1l, isg15 and/or ubp43
12/29/2004	EP1490077A1 A photoprotective orally administrable composition for skin
12/29/2004	EP1490072A1 Novel therapeutical use of agonist ligands specific to g2a receptor
12/29/2004	EP1490067A2 Use of tyrosine kinase inhibitors for treating substance use disorders
12/29/2004	EP1490063A1 Use of proton pump inhibitors for the treatment of noncardiac chest pain
12/29/2004	EP1490053A1 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
12/29/2004	EP1490051A1 Use of topoisomerase inhibitors and heat shock protein 90 inhibitors for use in chemotherapy
12/29/2004	EP1490050A2 Methods for alzheimer's disease treatment and cognitive enhancement
12/29/2004	EP1490049A1 Citalopram for the treatment of elevated blood pressure
12/29/2004	EP1490045A1 In vivo use of glutathionone s-transferase activated nitric oxide donors
12/29/2004	EP1490044A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
12/29/2004	EP1490042A2 Use of ltb4 antagonists in veterinary medicine
12/29/2004	EP1490041A1 Treatment of female sexual dysfunction
12/29/2004	EP1490034A1 Novel pharmaceutical compositions for antihistaminic-decongestant combination and method of making such compositions
12/29/2004	EP1490030A1 Nanoparticulate compositions of angiogenesis inhibitors
12/29/2004	EP1490027A1 Methods for entrapment of bioactive agent in a liposome or lipid complex
12/29/2004	EP1490025A2 Nanoparticulate compositions of map kinase inhibitors
12/29/2004	EP1490024A1 Effervescent compositions comprising bisphosphonates and methods related thereto
12/29/2004	EP1489988A1 Dispensing apparatus and cartridge
12/29/2004	EP1489924A2 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
12/29/2004	EP1274456B1 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
12/29/2004	EP1255821B1 Protein c derivatives
12/29/2004	EP1248623B1 Treatment of diabetic ulcers
12/29/2004	EP1226136B1 Tyrosine kinase inhibitors
12/29/2004	EP1216048B1 Solid lipid formulations comprising an inhibitor of lipases and a fatty acid ester of polyols
12/29/2004	EP1214345B1 Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth
12/29/2004	EP1210069B1 Large porous particles obtainable by spray-drying and suitable for pulmonary administration
12/29/2004	EP1202727B1 Use of agonists of gabab receptors and pharmaceutically acceptable derivatives thereof, in the therapy of maintaining nicotine abstinence in nicotine-dependent patients
12/29/2004	EP1196616B1 Replication-competent anti-cancer vectors
12/29/2004	EP1176140B1 Amide compounds and medicinal use thereof
12/29/2004	EP1163209A4 Compounds and compositions for delivering active agents
12/29/2004	EP1146909A4 Method of treating cancer by restoration of pp32 function
12/29/2004	EP1123509B1 Methods of diagnosing or prognosing alzheimer's disease
12/29/2004	EP1009400B1 Combination therapy comprising atorvastatin and an antihypertensive agent
12/29/2004	EP0994725B1 Thermodynamic adaptive phased array system for activating thermosensititve liposomes in targeted drug delivery
12/29/2004	EP0941092B1 Use of nk-1 receptor antagonists for treating major depressive disorders
12/29/2004	EP0920632B1 Methods for detection of autoimmune diseases
12/29/2004	EP0874626B1 Use of inhibitors of retinoic acid activity for wound healing
12/29/2004	EP0830130B9 Tnf-alpha converting enzyme
12/29/2004	EP0725635B1 Phenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders
12/29/2004	EP0722342B1 REGULATION OF bcl-2 GENE EXPRESSION
12/29/2004	CN1558915A Leukocyte inactivation module
12/29/2004	CN1558914A Receptor, the use thereof, and mouse antibodies
12/29/2004	CN1558905A Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
12/29/2004	CN1558894A Method for the nitration of phenolic compounds
12/29/2004	CN1558766A A method of reducing the 'in vivo' cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (HDL) and low density lipoproteins (LDL)
12/29/2004	CN1558764A Substituted urea neuropeptide Y Y5 receptor antagonists
12/29/2004	CN1558759A 病毒聚合酶抑制剂 Viral polymerase inhibitors
12/29/2004	CN1558758A Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine
12/29/2004	CN1558756A Pharmaceutical compositions for the treatment of urinary disorders
12/29/2004	CN1558755A Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
12/29/2004	CN1558754A Pharmaceutical dosage form with multiple coatings
12/29/2004	CN1182143C Bis-(N,N'-bis-(2-haloethyl) amino) phosphoramidates as antitumor agents
12/29/2004	CN1181821C Lesion-aimed antibiotics in dry dosage forms for treatment of shallow ulcers of oral mucosa
12/29/2004	CN1181819C Combination therapy using pentafluorobenzenesulfonamide
12/29/2004	CN1181738C Therapeutic anti-fungal nail preparation
12/29/2004	CA2530058A1 Mucin synthesis inhibitors
12/29/2004	CA2528718A1 Treatment of amd with combination of ingredients
12/29/2004	CA2527121A1 Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
12/29/2004	CA2526617A1 Diaryl ureas with kinase inhibiting activity
12/29/2004	CA2526563A1 Drug-containing sustained release microparticle, process for producing the same and preparation containing the microparticle
12/29/2004	CA2526423A1 Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure
12/28/2004	US6835750 Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
12/28/2004	US6835749 Sulfohydroxamic acids and sulfohydroxamates and their use as MEK inhibitors
12/28/2004	US6835717 Such as human immunodeficiency virus (HIV), herpes virus, Chlamydia spp., a Trichomona spp., or a Candida spp.
12/28/2004	US6835715 Mammalian dihydroouabain-like factor and therapeutic compositions
12/28/2004	US6835396 Energizing a multiphase system having an organic phase containing a poorly water soluble compound, e.g. drug, and an aqueous phase to form a fine dispersion; freeze drying; particularly for intravenous injection
12/28/2004	US6835372 Mixtures of di-(tri)peptides and drugs such as cyclosporin used as aerosols; drug delivery
12/28/2004	US6835370 Diagnosis and treatment of malignant neoplasms
12/28/2004	CA2316656C Electrolytic reduced water, anti-cancer drug, and producing method and apparatus thereof
12/28/2004	CA2268922C Methods of treating or preventing cardiac arrhythmia
12/28/2004	CA2245483C Fat based food products comprising sterols
12/23/2004	WO2004110492A2 Composition comprising triptans and nsaids
12/23/2004	WO2004110488A1 Drug for overcoming anticancer agent resistance and method of screening the same
12/23/2004	WO2004110473A1 Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent
12/23/2004	WO2004110463A1 Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc
12/23/2004	WO2004110461A1 Treatment of symptoms associated with bacterial vaginosis
12/23/2004	WO2004110450A1 Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases
12/23/2004	WO2004110428A1 Anti-inflammatory analgesic adhesive patch
12/23/2004	WO2004110422A1 Extended-release tablets of metformin
12/23/2004	WO2004110417A2 Compositions for the enhanced treatment of depression
12/23/2004	WO2004110415A2 Substituted 1, 4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opioid-based treatments
12/23/2004	WO2004110392A2 Compositions and methods for treating coronavirus infection and sars
12/23/2004	WO2004110383A2 Pharmaceutical composition and method for alleviating side effects of estrogen replacement therapy

1 ... 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 ... 1151